| CLINICAL REPORT
The patient was a product of an in vitro fertilization pregnancy to a 36-year-old mother and 41-year-old father (Supplemental Figure S1 ). She was born at 35 weeks via Cesarean delivery due to intrauterine growth restriction (IUGR). Her healthy male twin had no IUGR and is phenotypically normal. The patient's birth weight was 3 lbs 8 oz and she was hospitalized for 2 weeks for small size. At 3 months of age, she was diagnosed with left hip dysplasia for which she was treated with a brace. Developmental screening at 3 months of age was considered normal, however, at 10 months of age she was found to have global developmental delay. At the time of her first visit at 11-months-of age, her weight was on the 2nd centile (7.6 kg, Z-score −2.05), her height was on the 30th centile (72 cm, Z-score −0.53), and her OFC <1st centile (41.7 cm, Z-score −2.66).
All centiles and Z-scores are based on 2,000 Centers for Disease Control and Prevention (CDC) growth charts. The patient had microcephaly, brachycephaly,and plagiocephaly. Her face was notable for a round shape, small maxilla with slightly down slanting palpebral fissures, high arched eyelids, a short philtrum, and large ears. Both the high-arched eyelids and short philtrum are consistent with CS. Additionally, she had laryngomalacia. She was also found to have persistent neutropenia. This symptomatology was considered suggestive of CS.
| MATERIALS AND METHODS
Written informed consent was obtained from the patient's parents.
The data presented in this manuscript are not considered research at Baylor College of Medicine, as a single individual is investigated, and no generalizable conclusions can be drawn from this study. The investigators did, however, obtain signed consent for the publication of identifiable information, including the patient's photograph.
Genomic DNA was extracted from whole blood (Chemagen kit, PerkinElmer chemagen Technologie GmbH, Germany) from the patient and both parents. Array CGH was performed in the patient and each parent to determine inheritance and phase using a custom designed array manufactured by Agilent Technologies (Santa Clara, CA), as described previously (Boone et al., 2010) . Fluorescence in situ hybridization (FISH) analyses with the fosmid clones, (obtained from the Human Genome Center at Baylor College of Medicine) were performed to confirm the array analysis showing that the deletions are in trans as a quality control measure. Briefly, fosmid DNA was isolated using the Perfectprep mini kit (Eppendorf, Hamburg, Germany) and labeled using Spectrum Orange or Spectrum Green Vysis dUTPs (Vysis, Inc., Des Plaines, IL) according to the manufacturer's protocol.
Hybridization was performed using standard FISH protocol. In parallel with aCGH, exome sequencing was performed as described previously (Yang et al., 2013 (Yang et al., , 2014 Table S1 ). The parental DNA was run on one array, using the mother as a control sample and father as a test sample, with expected log ratio changes as in Table S1 . Analysis by FISH confirmed the presence of the deleted regions in trans in the patient (Supplemental Figure S2) .
| DISCUSSION
With increasing resolution and coverage of aCGH, and now that CNVs can be assessed with exome sequencing also, it is important to critically evaluate CNV results with the patient's phenotype. This is especially important for genes implicated in autosomal recessive disorders that are subject to copy number variation, such as VPS13B.
Accurate identification of intragenic CNVs is highly dependent on using the appropriate technology. Here, a high-resolution exon targeted aCGH was first used, as it is a first tier test for intellectual disability and chromosomal losses are known to be causative in CS.
With a lower resolution array, these intragenic CNVs can easily be missed. As this is a recessive disorder, exome sequencing was performed in parallel with aCGH to ensure no pathogenic variants were also contributing to the patient's phenotype. Depending on the process that is used, it may be possible to identify these large, non-contiguous, multi-exonic deletions by exome sequencing as well, although that was not performed at the time the patient was evaluated. When two or more non-contiguous intragenic CNVs are detected there are three interpretive possibilities: 1) the CNVs are in cis; 2) The CNVs are in trans; 3) Complex rearrangement such as an inversion, translocation, or an insertion that can be in cis or trans. At this point it is important to correlate the clinical data with the laboratory results in order to interpret the findings. In the present patient, the clinical presentation of CS with two noncontiguous deletions in the VPS13B gene and a negative exome sequencing report suggested that the two deletions may be in trans. Typically, our laboratory uses aCGH on parental samples to determine the inheritance of CNVs and in this family, it was found that both the parents are carriers for a deletion in VPS13B, and their child inherited both these deletions. FISH was also performed to confirm the finding though at this point it was not necessary but this was done to rule out additional rearrangements. The use of FISH could be valuable if the CNV is more than 20 kb to determine the phase in the patient cells, which is an important consideration for intragenic, non-contiguous, or contiguous deletions that may be in trans.
While this is the first report of two deletions in trans resulting in CS, the phenomenon of two deletions in trans resulting in an autosomal recessive disorder is not unique to VPS13B. Similar findings have been seen in patients with exon rearrangements in PARK2 (Kim et al., 2012) . Exon rearrangements account for up to 60% of PARK2 mutations, which are causative of early onset Parkinson disease (EOPD) with autosomal recessive inheritance. In a study of 114 Korean patients with EOPD, more than 80% diagnosed with contiguous multi-exon deletions were found to be actually in trans, once the phase of CNVs was determined (Kim et al., 2012 ).
This suggests that previous studies indicating that the patients' EOPD was caused by contiguous CNVs may actually have been multiple CNVs in trans. These patients and the current patient with CS emphasize that while molecular diagnoses can lead to answers, clinical information must be considered when interpreting these results. As these large multi-exonic CNVs can appear contiguous, it is important to consider if the clinical phenotype suggests that phase of the CNVs may play a role. This is particularly important for large genes known to be responsible for recessive disorders that are subject to multi-exonic CNVs.
In summary, we present a report of two small deletions in trans, in the VPS13B gene, in which autosomal recessive mutations or deletions are responsible for CS. Our findings highlight the importance of high-resolution aCGH and the critical analysis of aCGH data surrounding genes that are often impacted by genomic variation. Furthermore, our findings emphasize the need to understand the clinical phenotypes when interpreting diagnostic data and determining the appropriate assays to identify the molecular changes. The maternal sample was used as the control sample while the paternal sample was used as the test sample, with expected log ratios seen in Supplemental Table S1 . The paternal deletion of 130 kb is indicated by the log ratio of −1.0 while the maternal deletion of 66 kb is indicated by the log ratio of 1.0. [Color figure can be viewed at wileyonlinelibrary.com]
